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Background: A number of epidemiological studies indicate an inverse association between atopy and brain tumors in
adults, particularly gliomas. We investigated the association between atopic disorders and intracranial brain tumors in chil-
dren and adolescents, using international collaborative CEFALO data.
Patients and methods: CEFALO is a population-based case–control study conducted in Denmark, Norway, Sweden,
and Switzerland, including all children and adolescents in the age range 7–19 years diagnosed with a primary brain tumor
between 2004 and 2008. Two controls per case were randomly selected from population registers matched on age, sex,
and geographic region. Information about atopic conditions and potential confounders was collected through personal
interviews.
Results: In total, 352 cases (83%) and 646 controls (71%) participated in the study. For all brain tumors combined, there
was no association between ever having had an atopic disorder and brain tumor risk [odds ratio 1.03; 95% conﬁdence
interval (CI) 0.70–1.34]. The OR was 0.76 (95% CI 0.53–1.11) for a current atopic condition (in the year before diagnosis)
and 1.22 (95% CI 0.86–1.74) for an atopic condition in the past. Similar results were observed for glioma.
Conclusions: There was no association between atopic conditions and risk of all brain tumors combined or of glioma in
particular. Stratiﬁcation on current or past atopic conditions suggested the possibility of reverse causality, but may also
the result of random variation because of small numbers in subgroups. In addition, an ongoing tumor treatment may
affect the manifestation of atopic conditions, which could possibly affect recall when reporting about a history of atopic
diseases. Only a few studies on atopic conditions and pediatric brain tumors are currently available, and the evidence is
conﬂicting.
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introduction
Brain tumors account for the largest number of cancer deaths in
children, the second most common group of neoplasms, and the
largest group of pediatric solid tumors in developed countries
[1, 2]. Despite extensive research, the etiology of childhood
brain tumors remains largely unknown. The only established
risk factors are high doses of ionizing radiation, and rare genetic
disorders such as neuroﬁbromatosis I or Li–Fraumeni syndrome
[3–5]. However, these explain only a small fraction of the cases.
Epidemiological studies in adults have consistently reported
that atopic conditions, such as asthma, hay fever, or eczema, are
inversely associated with the risk of glioma but not consistently
with meningioma [6–8]. To date, there are only two studies
available on atopic conditions and brain tumors in childhood
[9, 10], with results compatible with those in adults.
The biological mechanism underlying this association is yet
to be elucidated. Two main hypotheses have been proposed: the
ﬁrst one, the immune surveillance hypothesis claims that the
presence of an atopic condition increases the immune system sur-
veillance to detect and eliminate malignant cells, contributing to†X.S. and M.P. contributed equally to this work.
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prevention of potential cancers [11–13]. The second hypothesis
claims that the association is reverse causality. The tumor itself is
known to be immunosuppressive, by affecting the balance
between Th1 and Th2 cytokines [14], and could potentially
prevent or mitigate atopic symptoms. This would lead to a lower
prevalence or decreased severity of atopic conditions among
brain tumor patients, including yet undiagnosed ones.
The aim of this study was to examine the association between
atopic conditions including asthma, wheezing, eczema, and al-
lergic rhinitis, and risk of intracranial brain tumors in children
and adolescents.
material and methods
The CEFALO study is a population-based multicenter case–control study
carried out in Denmark, Norway, Sweden, and Switzerland. The study
period was from 1 January 2004 through 31 August 2008, with slight time
variations between countries (Table 1).
case eligibility and ascertainment
Eligible cases were all children and adolescents diagnosed during the study
period with primary intracranial brain tumors in the age range 7–19 years.
All diagnoses were either histologically conﬁrmed or based on unequivocal
diagnostic imaging. Medical records for cases were examined to conﬁrm diag-
nosis and establish the date of diagnosis. The completeness of case ascertain-
ment was veriﬁed through searches in the population-based cancer registries
according to country-speciﬁc procedures. Brain tumors were classiﬁed accord-
ing to the International Classiﬁcation of Diseases tenth revision (ICD-10). Case
recruitment and tumor classiﬁcation are described in detail in Aydin et al. [15].
control eligibility and selection
Two controls per case were randomly selected from population registers in
the participating countries, matched on age, sex, and geographic region. In
Switzerland, a two-stage sampling procedure was applied for the selection of
controls in the absence of a national population registry. First, community
was randomly selected within the same language region as the case and
second, the control was randomly selected from the corresponding commu-
nal population registry. The reference date for controls was the date of diag-
nosis of the matched case.
exclusion criteria
Cases and controls diagnosed with neuroﬁbromatosis (Mb Recklinghausen)
or tuberose sclerosis, or completely deaf before the reference date or with
severe mental retardation were excluded. Additionally, families with insufﬁ-
cient language skills to complete an interview were excluded, as judged by
the nurse, treating physician, or project administrator.
data collection
Data collection started in June 2006 in all countries except Norway, where it
started in December 2007. Physician authorization for contact was obtained
for all cases, and both cases and controls provided signed informed consent.
The procedures varied between countries, depending on the requirements of
local ethics review boards. If the case was deceased, the parents were con-
tacted at the earliest 6 months after the death of the child.
Whenever possible, the child and at least one of the parents were inter-
viewed face-to-face by trained interviewers using a computer-assisted per-
sonal interview (CAPI) questionnaire (Denmark and Norway) or a paper
version of the questionnaire (Switzerland and Sweden). In exceptional cases,
telephone interviews were conducted with difﬁcult-to-reach subjects (4 con-
trols) or an adjusted paper version of the questionnaire was sent to the study
participant (19 controls). All interviews and contacts with the cases and con-
trols were made by interviewers employed for this purpose. Interviewers
from all centers received training at a joint workshop to ensure uniform data
collection. The translations of the questionnaire were checked through back-
translation to the master version (English), and the questionnaires were pilot
tested in all participating countries. The interviewer was not blinded regard-
ing the disease status. Interviews with a case and matched controls were
mainly carried out by the same interviewer.
The core questions used in the CEFALO study to identify atopic condi-
tions are based on the International study of asthma and allergies in child-
hood (ISAAC) [16]. The deﬁnitions of the atopic conditions are described in
the EAppendix. Categorization of atopic conditions was ascertained through
questions on whether the child had ever been diagnosed by a medical doctor
with asthma (ever/never), eczema (ever/never), or allergic rhinitis (ever/
never). Wheezing disorder (ever/never) was identiﬁed through a positive
answer on questions whether the child ever had wheezing or whistling in the
chest at any time in the past, but was not diagnosed with asthma. If the par-
ticipant answered ‘ever’, exposure status of this subject was further categor-
ized as ‘current’ if the child had at least one episode of the atopic condition
in the last 12 months before the diagnosis/reference date, or ‘past’ if the child
did not have any episode of the atopic condition in the last 12 months.
statistical methods
Estimates of odds ratios (ORs) and 95% conﬁdence intervals (CIs) were
obtained using conditional logistic regression for individually matched data-
sets. ORs were calculated for all atopic conditions combined, for speciﬁc
atopic conditions separately, and for ‘current’ and ‘past’ status of the atopic
Table 1. Descriptive characteristics of participants by study center, the CEFALO study
Denmark Norway Sweden Switzerland All
countries
Study period January 2004 to
April 2008
September 2004 to
August 2008
April 2004 to
August 2008
May 2004 to May
2008
Interviewed cases (participation rate, %) 85 (98) 44 (66) 138 (85) 85 (80) 352 (83)
Proxy interviews for diseased cases
(participation rate, %)
10 (12) 9 (20) 9 (7) 8 (9) 36 (10)
Interviewed controlsa
(participation rate, %)
170 (73) 78 (58) 228 (76) 170 (70) 646 (71)
Italic values show the number of case and percentage of proxy respondents in cases.
aNo proxy interviews were made for controls.
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conditions. The reference category consisted of children who had reported
no atopic condition at all. The analyses were made for all brain tumors com-
bined, and for glioma (ICD-O-3 morphology code: 9380-84, 9390-9393,
9400-9401, 9410-9411, 9420-9424, 9430, 9440-9442, 9444, 9450-9451, 9460)
and ‘other brain tumors’.
We tested the impact of potential confounders, such as family history of
cancer (yes/no), past medical radiation exposure to the head (yes/no),
smoking of the mother during pregnancy (yes/no), past head injuries (yes/
no), and infections (yes/no). Confounders that changed the OR by 10% or
more were included in the ﬁnal model. Adjustments for the child living on a
farm before the age of 6 years (yes/no) and for socioeconomic status were
made in all analyses.
All analyses were carried out using SAS statistical package v 9.3. (SAS
Institute, Inc., Cary, NC).
results
The distribution of cases and controls by study centers is shown
in Table 1. A total of 352 cases (83% of eligible) and 646 controls
(71%) participated in the study. Proxy respondents of the chil-
dren were interviewed for 10% of participating cases. The time
lag between date of interview and date of diagnosis (reference
date for control) ranged from 2 to 56 months for cases, and 2 to
57 months for controls, with the 25th, 50th, and 75th percentiles
at 11, 18, and 31 months for cases, and 12, 20, and 32 months
for controls.
Of the 352 participating cases, 83% were conﬁrmed by histo-
pathological examination. The majority of cases were diagnosed
with glioma (60%), with astrocytoma being the largest subgroup
(Table 2). Proportions of PNET in the group ‘other brain
tumors’ were 50% for cases below 15 years at diagnosis and 33%
for older cases.
Ever having had any of the atopic conditions was reported by
46% of both cases and controls. Asthma was reported by 13% of
cases and controls, while eczema was reported by 21% of cases
and 20% of controls. The results did not show an association
between ever having had an atopic condition and all brain
tumors combined or with glioma only, while a slightly but non-
signiﬁcantly reduced OR was observed for ‘other brain tumors’
(Table 3). ORs associated with speciﬁc types of atopic condi-
tions with all brain tumors combined or with glioma only were
all close to unity, but slightly lower effect estimates were
observed for ‘other brain tumors’, especially with eczema and al-
lergic rhinitis.
Effect estimates for all brain tumors combined or glioma with
a current diagnosis of an atopic condition were consistently
reduced, while effect estimates for those with a past atopic condi-
tion were slightly above unity, although with wide CIs (Table 4).
A similar pattern was observed for the four speciﬁc types of atopic
conditions. Further analysis of glioma demonstrated a lower risk
in females than males; however, none reached statistical signiﬁ-
cance (data not shown).
discussion
In this population-based case–control study, we did not observe
an association between ever having had an atopic condition and
brain tumor risk in children and adolescents. There were indica-
tions of reduced risk associated with a current atopic condition,
but this was accompanied by slightly raised risk for having had
an atopic condition in the past.
The suggestion that atopic conditions may be associated with
a reduced risk of developing brain tumors was introduced in the
early 1990s [17], and has been investigated in adults mainly in
case–control studies, but also a few cohort studies [6–8, 18, 19].
So far, there are only two case–control studies carried out
among children, with main results compatible with the ﬁndings
for adults [9, 10]. Our overall results are not in agreement with
the two previous studies on children. Harding et al. [10] found
greater risk reductions for PNET/medulloblastoma than for
pilocytic astrocytoma or glioma, and similar ﬁndings were
reported by Roncarolo et al. [9]. The older age-range included
in our study, 7–19 years compared with 0–14 years in the two
other studies might explain some of the differences, as the distri-
bution of brain tumor subtypes differs between the studies. The
number of children with PNET/medulloblastoma in our study
was small, and was grouped into the category ‘other tumors’,
where slightly reduced effect estimates were observed, but based
on small numbers. Nevertheless, the distribution of histological
subtypes of glioma in our study of 7–19 years olds differs con-
siderably compared with adults. The main type of adult glioma
Table 2. Distribution of brain tumors subgroups by age at diagnosis and gender, the CEFALO study
Age at diagnosis (years) Gender Total
<15 % 15–20 % Male % Female %
Glioma
Ependymoma 12 7 8 2 11 3 9 3 20
Astrocytoma 110 28 51 14 86 24 75 21 161
Other gliomas 18 5 12 3 13 4 17 5 30
Other brain tumors
PNETa 46 13 16 5 39 11 23 7 62
Other speciﬁed brain tumors 31 9 23 7 31 9 23 7 54
Unspeciﬁed brain tumors 15 4 10 3 10 3 15 4 25
Total 232 66 120 34 190 54 162 46 352
aPrimitive neuroectodermal tumors.
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Table 3. Atopic conditions and risk of brain tumors, the CEFALO study
All brain tumors Glioma (ependymoma,
astrocytoma, other gliomas)
Other brain tumors (PNET, other
speciﬁed brain tumors,
unspeciﬁed brain tumors)
Cases
(N = 352)
Controls
(N = 646)
ORa 95% CI Cases Controls ORa 95% CI Cases Controls ORa 95% CI
Reference (no atopic
condition)
191 349 1.00 106 205 1.00 85 144 1.00
Any atopic condition
Everb 160 293 1.03 0.70–1.34 104 174 1.18 0.84–1.67 56 119 0.82 0.54–1.25
Number of atopic conditions
One 103 190 1.01 0.75–1.36 62 115 1.09 0.74–1.60 41 75 0.90 0.57–1.43
Two or more 55 100 1.09 0.74–1.59 40 58 1.43 0.88–2.32 15 42 0.68 0.36–1.31
Type of atopic conditions
Asthma
Ever 47 85 0.95 0.60–1.49 32 49 0.99 0.54–1.82 15 36 0.85 0.41–1.76
Wheezingc
Ever 41 78 1.19 0.72–1.96 23 43 1.23 0.59–2.57 18 35 1.16 0.58–2.31
Eczema
Ever 75 127 1.01 0.69–1.48 52 72 1.37 0.85–2.22 23 55 0.60 0.31–1.17
Allergic rhinitis
Ever 62 135 0.81 0.55–1.21 45 81 1.11 0.68–1.83 17 54 0.47 0.23–0.96
aMatched analyses adjusted for living on a farm before age 6 and socioeconomic status.
bOne case and four controls were excluded because of missing information.
cUsed for children with reported wheeze without a diagnosis of asthma.
Table 4. Current/past atopic condition and risk of brain tumors, the CEFALO study
All brain tumors Glioma (ependymoma, astrocytoma,
other gliomas)
Other brain tumors (PNET, other
speciﬁed brain tumors,
unspeciﬁed brain tumors)
Cases
(N = 352)
Controls
(N = 646)
ORa 95% CI Cases Controls ORa 95% CI Cases Controls ORa 95% CI
Reference (no atopic
condition)
191 349 1.00 106 205 1.00 85 144 1.00
Any atopic conditionb
Current 57 134 0.76 0.53–1.11 37 86 0.81 0.50–1.29 20 48 0.69 0.38–1.27
Past 79 115 1.22 0.86–1.74 50 63 1.45 0.91–2.30 29 52 0.96 0.55–1.66
Type of atopic conditions
Asthma
Current 19 39 0.81 0.41–1.60 15 22 0.97 0.42–2.25 4 17 0.41 0.10–1.64
Past 20 36 1.00 0.51–1.95 13 22 0.89 0.36–2.22 7 14 1.01 0.35–2.89
Wheezingc
Current 10 27 0.93 0.36–2.41 5 15 0.42 0.08–2.14 5 12 1.50 0.44–5.09
Past 29 40 1.33 0.74–2.39 16 20 1.75 0.70–4.36 13 20 1.12 0.51–2.48
Eczema
Current 23 52 0.79 0.43–1.48 15 34 0.89 0.41–1.93 8 18 0.78 0.26–2.33
Past 31 44 1.17 0.65–2.09 20 23 1.75 0.76–3.29 11 21 0.58 0.21–1.61
Allergic rhinitis
Current 46 105 0.76 0.48–1.19 33 61 1.10 0.62–1.96 13 44 0.39 0.17–0.86
Past 7 5 2.65 0.61–11.44 7 2 7.93 0.89–70.38 0 3
aMatched analyses adjusted for living on a farm before age 6 and socioeconomic status.
bThe number of ‘current’ and ‘past’ do not add up due to missing information on diagnosis date of atopic conditions.
cUsed for children with reported wheeze without a diagnosis of asthma.
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are stage 4 (>50% glioblastoma), and the rest are mainly stage 3
or 2, while most gliomas in children are stage 1 (pilocytic astro-
cytoma). Furthermore, there is evidence [20] that grade 1 glioma
does not develop through the stages in children. This may explain
the discrepancy observed between our previous study on adults
[6] and the present study.
In our study on adults [6], we found that the reduced glioma
risk was primarily associated with an ongoing atopic condition,
whereas risk estimates were close to unity for individuals who
had had an atopic condition in the past, but not at the time of
glioma diagnosis. This ﬁnding was interpreted as being in agree-
ment with the immune surveillance hypothesis, indicating that an
active immune system might be protective. Caution was, however,
expressed, as an alternative explanation could be reverse caus-
ation. The immunosuppressive effect of the tumor itself [21, 22]
could make atopic conditions in cases disappear, and these
subjects would consequently move to the ‘past allergy’ group.
Accordingly, the expected pattern with brain tumor is an associ-
ation below unity with current atopic conditions and a raised risk
estimate with past atopic conditions. On the other hand, whether
any of these hypotheses is relevant for children depends on grade
1 gliomas having similar immunosuppressive effects as grade 4
gliomas which seems unlikely but is largely unknown. Another
low-grade tumor, meningioma, did not show an inverse relation-
ship between atopic disease and tumor incidence in adults [7]. In
addition, two recent studies of glioma in adults found an inverse
association between prediagnostic IgE levels and glioma risk [19,
23], one of which [19] measured IgE levels as early as 20 years
before diagnosis which speak against reverse causation. In the
current study, however, we found an indication of reduced risk
estimates associated with current atopic conditions, which was
accompanied with raised risk estimates for past atopic conditions.
These ﬁndings were, however, based on small numbers of subjects
in the subgroups, and may also be explained by random variation.
In addition, an ongoing chemo- and/or radiation therapy may
affect the manifestation of atopic conditions [24], which could
possibly affect recall when reporting about a history of atopic
diseases.
To our knowledge, the association between allergic rhinitis,
also known as hay fever, and brain tumor development has not
previously been studied in children. We found a reduced risk
primarily in the group ‘other brain tumors’, but not for glioma.
Studies in adults have shown an inverse association between al-
lergic rhinitis and glioma [6, 25], although not consistently [26].
The strengths of our study are the population-based control
selection, identiﬁcation of cases through high-quality popula-
tion-based cancer registers and close collaboration with pediat-
ric oncology and neurosurgery clinics, a detailed structured
interviewer-administered questionnaire, and collection of exten-
sive information on covariates. Recall bias caused by mental
modiﬁcations could be reduced to a minimum because ques-
tions were answered by both the child and the parents together.
However, some limitations should be considered. The study
had relatively high response rates, but we were nevertheless
unable to recruit 29% of the selected controls and 17% of the eli-
gible cases. Nonparticipation would not inﬂuence study results
unless prevalence of atopic conditions are believed to differ
between the included and non-included controls in a different
manner than between included and nonincluded cases. Due to
the roughly comparable participation rates, this seems very un-
likely. Other limitations common to case–control studies is the
risk of misclassiﬁcation of exposure history. As in previous
studies on children and adults, we measured atopic conditions
through self-reports, which may be subject to misclassiﬁcation
errors and could lead to a dilution of risk estimates, if independ-
ent of case–control status. Obtaining a brain tumor diagnosis is
a severe life-threatening event and may result in underreporting
of atopic conditions in cases but not controls, which would
explain decreased ORs for current atopic conditions but not
increased odds ratios for past conditions. The reported preva-
lence of atopic conditions in our study is in accordance with
other studies [10, 27]. In studies of self-reported atopic condi-
tions in adults, the sensitivity for the question about self-
reported asthma in relation to a clinical diagnosis of asthma was
68% in the reviewed studies (range 48–100%), and the speciﬁcity
was 94% (range 78–100%) [28].
In conclusion, our results do not support an association between
atopic conditions and risk of brain tumors overall in children and
adolescents or of glioma in particular. Results stratiﬁed on current
or past atopic conditions indicated a possibility of reverse causality,
but these subgroup ﬁndings may also be explained by random vari-
ation. Only a few studies on atopic conditions and pediatric brain
tumors are currently available, and the evidence is conﬂicting.
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